Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07889570
NA

A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression

Sponsor: Evolv

View on ClinicalTrials.gov

Summary

This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association. The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

98

Start Date

2026-04-01

Completion Date

2026-07-01

Last Updated

2026-10-22

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Evolv GLP-1 Group

Participants take 8 capsules of Evolv GLP-1 daily (4 capsules in the morning and 4 capsules in the evening) for 12 weeks.

OTHER

Control Group

Participants receive a standardized recommendation for healthy eating from the American Diabetes Association (https://diabetesfoodhub.org/blog/what-diabetes-plaand do not receive any study product.

Locations (1)

Citruslabs

Las Vegas, Nevada, United States